한글목차

급성 근긴장이상증 세계 시장은 2025년에는 1억 2,080만 달러로 추정되며, 2032년에는 1억 5,260만 달러에 달할 것으로 예상되며, 2025-2032년 동안 3.4%의 CAGR로 성장할 것으로 예상됩니다.

그림. 급성 근긴장이상증 세계 시장 점유율(%), 지역별, 2025년

급성 근긴장이상증은 반복적인 운동이나 비정상적인 자세로 이어지는 비자발적인 근육 수축을 특징으로 하는 운동 장애입니다. 이러한 수축은 통증을 동반할 수 있으며, 종종 갑작스러운 근육 경련으로 인해 발생합니다. 급성 근긴장이상증은 경부(경부 근긴장이상증), 눈(안구 근긴장이상증), 턱이나 혀, 사지 등 신체의 모든 부위에 영향을 미칠 수 있습니다. 이 증상에는 다음과 같은 다양한 원인이 있습니다.

• 약물성 근긴장이상증 : 가장 흔한 원인 중 하나입니다. 특정 약물, 특히 뇌의 도파민 경로에 영향을 미치는 항정신병 약물의 부작용으로 발생할 수 있습니다.
• 특발성 근긴장이상증 : 원인 불명.
• 이차성 근긴장이상증 : 윌슨병, 헌팅턴병, 파킨슨병, 뇌손상, 뇌졸중 등 기저질환에 기인합니다.

시장 역학

세계 급성 근긴장이상증 시장은 파킨슨병, 뇌성마비, 지연성 운동 이상증과 같은 급성 근긴장이상증를 유발하는 신경 질환의 유병률 증가에 의해 주도되고 있습니다. 예를 들어, 2024년 8월 9일 세계보건기구(WHO)가 발표한 보고서에 따르면 파킨슨병(PD)은 운동, 정신건강, 수면, 통증 및 기타 건강 문제를 유발하는 뇌 질환입니다. 미국에서는 2021년 100만 명에 가까운 사람들이 파킨슨병(PD)을 앓고 있으며, 2030년에는 120만 명으로 증가할 것으로 예측됩니다. 파킨슨병은 알츠하이머병에 이어 두 번째로 흔한 신경 퇴행성 질환입니다.

또한 2022년 3월 미국 국립생물공학정보센터가 발표한 보고서에 따르면 매년 미국 유아 1,000명 중 2.3-3.6명이 뇌성마비를 앓고 있다고 합니다. 경련성 뇌성마비가 가장 많으며 전체 뇌성마비의 61%에서 76.9%를 차지합니다.

본 조사의 주요 특징

• 세계의 급성 근긴장이상증 시장에 대해 조사분석했으며, 2024년을 기준 연도로 하여 예측 기간(2025-2032년)의 시장 규모와 연평균 성장률(CAGR)을 조사하여 전해드립니다.
• 또한, 다양한 부문에 걸친 잠재적인 수익 성장 기회를 밝히고, 이 시장의 매력적인 투자 제안 매트릭스를 설명합니다.
• 또한 시장 촉진요인, 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 주요 기업의 경쟁 전략 등에 대한 중요한 인사이트를 제공합니다.
• 이 보고서는 기업 하이라이트, 제품 포트폴리오, 주요 하이라이트, 성과, 전략 등의 매개 변수를 기반으로 세계 급성 근긴장이상증 시장의 주요 기업 프로파일을 제공합니다.
• 이 보고서의 인사이트를 통해 마케팅 담당자와 기업 경영진은 향후 제품 출시, 유형화, 시장 확대, 마케팅 전술에 대한 정보에 입각한 의사결정을 내릴 수 있습니다.
• 급성 근긴장이상증 세계 시장 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 참가자, 재무 분석가 등 이 산업의 다양한 이해관계자를 대상으로 합니다.
• 이해관계자들은 세계 급성 근긴장이상증 시장 분석에 사용되는 다양한 전략 매트릭스를 통해 의사결정을 쉽게 내릴 수 있습니다.

목차

제1장 조사 목적과 가정

• 조사 목적
• 가정
• 약어

제2장 시장 전망

• 보고서 설명
  • 시장 정의와 범위
• 주요 요약
• Coherent Opportunity Map(COM)

제3장 시장 역학, 규제, 동향 분석

• 시장 역학
  • 근긴장이상증 유병률 증가
  • 약에 따른 부작용
  • 변화하는 치료 패턴을 이해한다
• 규제 가이드라인
• 시장 동향
• PEST 분석
• 투자와 자금 조달
• 합병, 인수, 제휴
• 제품 매핑
• 상위 시장 진출 기업 특정
• 시장 진입 기업에 의한 다양한 사업 개발 전략 채용
• 국가에 의한 의료비 지출

제4장 세계의 급성 근긴장이상증 시장 - 코로나바이러스(COVID-19) 팬데믹의 영향

• COVID-19 역학
• 공급측과 수요측 분석
• 경제에 대한 영향

제5장 급성 근긴장이상증 세계 시장, 약물 종류별, 2020-2032년

• 소개
• 항콜린제
• 벤조디아제핀
• 기타(신경독 등)

제6장 급성 근긴장이상증 세계 시장, 연령층별, 2020-2032년

• 소개
• 유아
• 성인

제7장 급성 근긴장이상증 세계 시장, 유통 채널별, 2020-2032년

• 소개
• 병원 약국
• 소매 약국
• 온라인 약국

제8장 급성 근긴장이상증 세계 시장, 지역별, 2020-2032년

• 소개
• 북미
• 유럽
• 아시아태평양
• 라틴아메리카
• 중동
• 아프리카

제9장 경쟁 구도

• 기업 개요
  • Fresenius Kabi
  • Amar Healthcare
  • Johnson & Johnson
  • PAI Pharma
  • Pfizer Inc.
  • Souvin Pharmaceuticals Pvt.Ltd
  • Bayer Healthcare
  • SSPharmachem
  • Remedy Labs
  • Wan Bury
  • F. Hoffmann-La Roche Ltd
  • Bausch Health Companies, Inc.
  • Viatris Inc.
  • Teva Pharmaceutical Industries Ltd
  • Torrent Pharmaceuticals Ltd.
  • Mallinckrodt Pharmaceuticals
  • Amneal Pharmaceuticals LLC
  • Sun Pharmaceutical Industries Ltd.
  • Aurobindo Pharma Ltd.

제10장 섹션

• 참고문헌
• 조사 방법
• 출판사 소개

영문목차

Global Acute Dystonia Market is estimated to be valued at USD 120.8 Mn in 2025 and is expected to reach USD 152.6 Mn by 2032, growing at a compound annual growth rate (CAGR) of 3.4% from 2025 to 2032.

Figure. Global Acute Dystonia Market Share (%), By Region 2025

Acute dystonia is a movement disorder characterized by involuntary muscle contractions that lead to repetitive movements or abnormal postures. These contractions can be painful and are often caused by a sudden onset of muscle spasms. Acute dystonia can affect any part of the body, including the neck (cervical dystonia), eyes (oculogyric crisis), jaw or tongue, and the limbs. The condition can have varying causes, including:

• Drug-induced Dystonia: One of the most common causes. It can occur as a side effect of certain medications, particularly antipsychotic drugs that affect dopamine pathways in the brain.
• Idiopathic Dystonia: Where the cause is unknown
• Secondary Dystonia: Resulting from an underlying medical condition such as Wilson's disease, Huntington's disease, Parkinson's disease, brain injury, or stroke

Market Dynamics:

The global acute dystonia market is driven by the rising prevalence of neurological disorders that can induce acute dystonia like Parkinson's disease, cerebral palsy, and tardive dyskinesia. For instance, on August 9, 2024, according to a report published by the World Health Organization (WHO), Parkinson's disease (PD) is a brain condition that causes problems with movement, mental health, sleep, pain, and other health issues. Nearly one million people in the U.S. were living with Parkinson's disease (PD) in 2021, while this number is expected to rise to 1.2 million by 2030. Parkinson's disease is the second-most common neurodegenerative disease after Alzheimer's disease.

Furthermore, in March 2022, according to a report published by the National Center for Biotechnology Information, cerebral palsy occurs in 2.3 to 3.6 out of every 1,000 children in the U.S., every year. While spastic cerebral palsy is the most common, making up 61 percent to 76.9 percent of all cerebral palsy cases.

Key Features of the Study:

• This report provides an in-depth analysis of the global acute dystonia market, and provides market size (US$ Mn) and compound annual growth rate (CAGR %) for the forecast period (2025-2032), considering 2024 as the base year
• It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global acute dystonia market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Fresenius Kabi, Amar Healthcare, Johnson & Johnson ,PAI Pharma, Pfizer Inc., Souvin Pharmaceuticals Pvt.Ltd, Bayer Healthcare, S.S.Pharmachem, Remedy Labs, Wan Bury, F. Hoffmann-La Roche Ltd, Bausch Health Companies, Inc., Viatris Inc. , Teva Pharmaceutical Industries Ltd, Torrent Pharmaceuticals Ltd., Mallinckrodt Pharmaceuticals, Amneal Pharmaceuticals LLC, Sun Pharmaceutical Industries Ltd., and Aurobindo Pharma Ltd.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global acute dystonia market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global acute dystonia market

Detailed Segmentation:

• Global Acute Dystonia Market, By Drug Class
  • Anticholinergic Agents
  • Benzodiazepines
  • Others (Neurotoxin, etc.)
• Global Acute Dystonia Market, By Age Group
  • Children
  • Adult
• Global Acute Dystonia Market, By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• Global Acute Dystonia Market, By Region
  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East
  • Africa
• Company Profiles
  • Fresenius Kabi
  • Amar Healthcare
  • Johnson & Johnson
  • PAI Pharma
  • Pfizer Inc.
  • Souvin Pharmaceuticals Pvt.Ltd
  • Bayer Healthcare
  • S.Pharmachem
  • Remedy Labs
  • Wan Bury
  • F.Hoffmann-La Roche Ltd
  • Bausch Health Companies, Inc.
  • Viatris Inc.
  • Teva Pharmaceutical Industries Ltd
  • Torrent Pharmaceuticals Ltd.
  • Mallinckrodt Pharmaceuticals
  • Amneal Pharmaceuticals LLC
  • Sun Pharmaceutical Industries Ltd.
  • Aurobindo Pharma Ltd.

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snippet, By Drug Class
  • Market Snippet, By Age Group
  • Market Snippet, By Distribution Channel
  • Market Snippet, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Increasing prevalence of dystonia
  • Side effects associated with drugs
  • Understanding changing treatment patterns
• Key Highlights
• Regulatory Guidelines
• Market Trends
• PEST Analysis
• Investments and Funding
• Mergers, Acquisitions, and Collaborations
• Product Mapping
• Identification of Top Market Players
• Adoption of Various Business Development Strategies by the Market players
• Healthcare Spending by Country

4. Global Acute Dystonia Market - Impact of Coronavirus (COVID-19) Pandemic

• COVID-19 Epidemiology
• Supply Side and Demand Side Analysis
• Economic Impact

5. Global Acute Dystonia Market, By Drug Class, 2020-2032, (US$ Mn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Anticholinergic Agents
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
• Benzodiazepines
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
• Others (Neurotoxin, etc.)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)

6. Global Acute Dystonia Market, By Age Group, 2020-2032, (US$ Mn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Children
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
• Adult
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)

7. Global Acute Dystonia Market, By Distribution Channel, 2020-2032, (US$ Mn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Hospital Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
• Retail Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
• Online Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)

8. Global Acute Dystonia Market, By Region, 2020-2032, (US$ Mn)

• Introduction
  • Market Share Analysis, By Region, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, For Region, 2021 - 2032
  • Country Trends
• North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020-2032,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2020-2032,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Mn)
    • U.S.
    • Canada
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020-2032,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2020-2032,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Mn)
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020-2032,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2020-2032,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Mn)
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020-2032,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2020-2032,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Mn)
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
• Middle East
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020-2032,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2020-2032,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Mn)
    • GCC Countries
    • Israel
    • Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020-2032,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2020-2032,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2020-2032,(US$ Mn)
    • North Africa
    • Central Africa
    • South Africa

9. Competitive Landscape

• Company Profile
  • Fresenius Kabi
• Company Highlights
• Product Portfolio
• Key Highlights
• Financial Performance
• Strategies
  • Amar Healthcare
  • Johnson & Johnson
  • PAI Pharma
  • Pfizer Inc.
  • Souvin Pharmaceuticals Pvt.Ltd
  • Bayer Healthcare
  • S.S.Pharmachem
  • Remedy Labs
  • Wan Bury
  • F. Hoffmann-La Roche Ltd
  • Bausch Health Companies, Inc.
  • Viatris Inc.
  • Teva Pharmaceutical Industries Ltd
  • Torrent Pharmaceuticals Ltd.
  • Mallinckrodt Pharmaceuticals
  • Amneal Pharmaceuticals LLC
  • Sun Pharmaceutical Industries Ltd.
  • Aurobindo Pharma Ltd.
• Analyst Views

10. Section

• References
• Research Methodology
• About us